StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) shareholders

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
97.4%
42M of 43M shares
Institutional holders
878
107 new, 70 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 2901 sales
Net sold $1.43B

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
BlackRock, Inc.5,294,84411.30%13G (passive) amendmentDec 31, 2023
Behzad Aghazadeh
Joint filing with Avoro Capital Advisors LLC (6.10%)
2,858,8886.10%13G (passive) amendmentDec 31, 2023
Wellington Investment Advisors Holdings LLP
Joint filing with Wellington Management Group LLP (5.50%), Wellington Group Holdings LLP (5.50%)
2,463,8915.50%13G (passive) amendmentDec 31, 2024
Wellington Group Holdings LLP
Joint filing with Wellington Management Group LLP (5.70%), Wellington Investment Advisors Holdings LLP (5.70%)
2,441,4925.70%13G (passive)Dec 31, 2025
Rothblatt Martine A2,333,7215.30%13G (passive) amendmentJun 30, 2026
Vanguard Capital Management2,278,3485.19%13G (passive)Mar 31, 2026
United Therapeutics Corporation1100.00%13D (active)Dec 12, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of UTHRValueChange% of portfolio
BlackRock, Inc.5,294,52912.34%$2.87B−105,1200.04%
Avoro Capital Advisors LLC2,777,7776.48%$1.51B+147,77713.52%
Vanguard Portfolio Management LLC1,919,4294.48%$1.04B−84,3130.05%
Vanguard Capital Management LLC1,918,2564.47%$1.04B−39,2830.02%
State Street Corp1,898,0644.43%$1.03B+54,1010.03%
Renaissance Technologies LLC1,708,7393.98%$925.85M−78,2801.27%
Wellington Management Group Llp1,379,0253.22%$747.20M−885,2220.13%
Geode Capital Management, LLC996,5982.32%$538.86M−236,4310.03%
Jupiter Topco LLC831,1291.94%$450.14MNew0.18%
Norges Bank694,7531.62%$376.44MNew0.04%
Assetmark, Inc624,0681.46%$338.14M+8,0180.58%
Aqr Capital Management LLC546,0021.27%$294.64M−280,2240.10%
Dimensional Fund Advisors LP527,9041.23%$286.05M+15,1650.05%
FMR LLC473,4091.10%$256.51M−54,9370.01%
Invesco Ltd.473,1091.10%$256.34M−135,2580.02%
Baillie Gifford & Co467,2091.09%$253.15M+39,0820.23%
Deerfield Management Company, L.P. (Series C)457,0001.07%$247.62M–2.58%
Morgan Stanley436,6991.02%$236.62M+27,4110.01%
Vestal Point Capital, LP435,0001.01%$235.70M+360,0005.51%
Northern Trust Corp430,8441.00%$233.44M−5,7220.03%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202687842M97.4%107 / 317331 / 705M4M
Q1 202685442M96.8%114 / 301322 / 868M4M
Q4 202583742M98.3%201 / 281259 / 547M5M
Q3 202570841M96.1%112 / 212286 / 665M7M
Q2 202567144M100.0%77 / 283220 / 714M5M
Q1 202567245M100.0%91 / 255229 / 814M3M
Q4 202467344M100.0%104 / 269211 / 453M3M
Q3 202462644M100.0%112 / 205228 / 489M5M
Q2 202456846M100.0%105 / 200195 / 556M6M
Q1 202452447M100.0%55 / 214182 / 616M5M
Q4 202353545M100.0%78 / 202169 / 414M3M
Q3 202350845M100.0%72 / 174180 / 342M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

654 funds held UTHR in Q2 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of UTHRValue% of fundAs of
iShares Core S&P Mid-Cap ETF1,452,5983.39%$787.06M0.63%Jun 30, 2026
Vanguard Total Stock Market Index Fund1,347,7203.14%$730.24M0.03%Jun 30, 2026
Vanguard Small-Cap Index Fund973,4902.27%$527.47M0.28%Jun 30, 2026
Vanguard Health Care Fund719,3851.68%$372.43M0.98%Jul 31, 2026
Vanguard Extended Market Index Fund486,5551.13%$263.63M0.27%Jun 30, 2026
Vanguard Small-Cap Value Index Fund308,3280.72%$167.06M0.25%Jun 30, 2026
Vanguard U.S. Growth Fund304,1300.71%$169.35M0.36%May 31, 2026
iShares Biotechnology ETF290,8000.68%$157.56M1.73%Jun 30, 2026
Vanguard Small-Cap Growth Index Fund280,7580.65%$152.12M0.32%Jun 30, 2026
Invesco S&P MidCap Quality ETF266,1630.62%$137.80M2.53%Jul 31, 2026
iShares S&P Mid-Cap 400 Growth ETF253,9570.59%$137.60M1.22%Jun 30, 2026
Franklin Dynatech Fund225,0000.52%$121.91M0.40%Jun 30, 2026
Fidelity Extended Market Index Fund221,8830.52%$123.55M0.29%May 31, 2026
State Street(R) SPDR(R) Portfolio S&P 400(TM) Mid Cap ETF214,8790.50%$116.43M0.63%Jun 30, 2026
Fullerthaler Behavioral Small Cap Equity204,4710.48%$110.79M0.88%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Martine A. RothblattChairperson & CEO, Director365,1220.85%Nov 17, 2026
Paul A. MahonEVP & GENERAL COUNSEL45,1720.11%Nov 5, 2026
James EdgemondCFO AND TREASURER25,5060.06%Jun 23, 2026
Michael BenkowitzPRESIDENT AND COO36,4620.09%May 14, 2026
Christopher PatuskyDirector3,2400.01%Nov 10, 2026
Nilda MesaDirector5,5800.01%Sep 15, 2026
Tommy G. ThompsonDirector22,4800.05%Jul 23, 2026
Judy D. OlianDirector5,5550.01%Jul 23, 2026
Kevin TraceyDirector––Jul 23, 2026
Jan MalcolmDirector4500.00%Jul 23, 2026
Linda MaxwellDirector2,0000.00%Jul 23, 2026
Christopher CauseyDirector4,1900.01%Jul 23, 2026
Louis W. SullivanDirector4,4400.01%Jul 23, 2026
Ray KurzweilDirector13,3200.03%Jul 23, 2026
Victor J. DzauDirector––Jul 23, 2026
Richard GiltnerDirector21,8840.05%Jul 23, 2026
Raymond DwekDirector4,7500.01%Jul 28, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−120$595.19$71.42K324,443
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−200$594.60$118.92K324,563
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−240$593.16$142.36K324,763
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−514$592.05$304.31K325,003
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−996$591.26$588.89K325,517
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−575$590.25$339.39K326,513
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−835$588.59$491.47K327,088
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−1,090$587.61$640.49K327,923
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−2,108$586.72$1.24M329,013
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−1,382$585.83$809.62K331,121
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−640$584.54$374.10K332,503
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−240$583.61$140.07K333,143
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−280$582.18$163.01K333,383
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−170$581.25$98.81K333,663
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Sale(10b5-1 plan)−110$580.25$63.83K333,833
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 16, 2026Option exercise+9,500$117.76$1.12M333,943
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−40$598.83$23.95K324,443
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−440$597.48$262.89K324,483
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−480$596.65$286.39K324,923
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−1,040$595.41$619.23K325,403
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−1,275$594.65$758.18K326,443
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−245$593.81$145.48K327,718
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−518$592.61$306.97K327,963
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−2,181$591.56$1.29M328,481
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−1,657$590.65$978.70K330,662
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−603$589.80$355.65K332,319
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−493$588.61$290.18K332,922
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Sale(10b5-1 plan)−528$587.42$310.16K333,415
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 13, 2026Option exercise+9,500$117.76$1.12M333,943
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−280$597.33$167.25K324,443
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−662$596.22$394.70K324,723
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−1,409$595.17$838.59K325,385
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−3,079$594.24$1.83M326,794
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−1,934$593.44$1.15M329,873
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−551$592.32$326.37K331,807
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−317$591.10$187.38K332,358
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−359$590.11$211.85K332,675
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−427$589.21$251.59K333,034
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−323$588.30$190.02K333,461
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Sale(10b5-1 plan)−159$587.00$93.33K333,784
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 12, 2026Option exercise+9,500$117.76$1.12M333,943
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−247$598.63$147.86K324,443
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−1,299$597.61$776.30K324,690
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−1,324$596.74$790.08K325,989
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−1,346$595.46$801.48K327,313
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−991$594.66$589.31K328,659
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−961$593.57$570.42K329,650
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−1,172$592.68$694.63K330,611
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−736$591.56$435.39K331,783
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−301$590.31$177.68K332,519
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−292$589.18$172.04K332,820
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−271$588.16$159.39K333,112
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−320$586.59$187.71K333,383
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−215$585.93$125.98K333,703
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Sale(10b5-1 plan)−25$584.20$14.61K333,918
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 11, 2026Option exercise+9,500$117.76$1.12M333,943
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 10, 2026Sale(10b5-1 plan)−80$592.93$47.43K324,443
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 10, 2026Sale(10b5-1 plan)−120$592.20$71.06K324,523
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 10, 2026Sale(10b5-1 plan)−960$590.95$567.32K324,643
Martine A. Rothblatt
Chairperson & CEO, Director
Nov 10, 2026Sale(10b5-1 plan)−2,040$589.95$1.20M325,603

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
4.71%
2M shares short
Days to cover
3.5
At 1M shares a day
Change since last report
-25.2%
From 2M shares
Short volume, 20 days
53.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of United Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,582 shares on Aug 21, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Christopher Patusky
Director
Nov 9, 20261,210$701.80KNov 9, 2026Stock Option Exercise
Paul A. Mahon
Officer
Nov 5, 20268,300$4.97MNov 5, 2026Stock Option Exercise
Martine A. Rothblatt
Director, Officer
Nov 2, 2026119,410$71.49MNov 2, 2026Exercise of Stock Options
Paul A. Mahon
Officer
Oct 15, 20268,300$4.52MOct 15, 2026Stock Option Exercise
Martine A. Rothblatt
Director, Officer
Oct 1, 2026209,000$113.26MOct 1, 2026Exercise of Stock Options
Paul A. Mahon
Officer
Oct 1, 20268,300$4.69MOct 1, 2026Stock Option Exercise
Paul A. Mahon
Officer
Sep 17, 20268,300$4.13MSep 17, 2026Stock Option Exercise
Nilda Mesa
Director
Sep 14, 2026228$115.34KSep 14, 2026Stock Option Exercise
Paul A. Mahon
Officer
Sep 3, 20268,300$4.00MSep 3, 2026Stock Option Exercise
Martine A. Rothblatt
Officer
Sep 1, 2026199,500$101.82MSep 1, 2026Exercise of Stock Options
Paul A. Mahon
Officer
Aug 20, 20268,300$4.34MAug 20, 2026Stock Option Exercise
Paul A. Mahon
Officer
Aug 6, 20268,300$4.29MAug 6, 2026Stock Option Exercise
Martine A. Rothblatt
Director, Officer
Aug 3, 2026199,500$103.28MAug 3, 2026Exercise of Stock Options
Paul A. Mahon
Officer
Jul 16, 20268,300$4.43MJul 16, 2026Stock Option Exercise
Jan Malcolm
Director
Jul 10, 2026325$178.94KJul 10, 2026Restricted Stock

Congress trades

7 trades in United Therapeutics reported by 3 members of the House

MemberTypeTradedAmountFiled
Lisa McClain
MI09 · spouse
SoldOct 31, 2025$1K–15KNov 21, 2025
Lisa McClain
MI09 · spouse
SoldOct 30, 2025$1K–15KNov 21, 2025
Lisa McClain
MI09 · spouse
BoughtOct 30, 2025$1K–15KNov 21, 2025
Lisa McClain
MI09 · spouse
BoughtJun 11, 2025$1K–15KAug 13, 2025
63 days late
Michael T. McCaul
TX10 · child
BoughtJun 18, 2021$1K–15KJul 16, 2021
Michael T. McCaul
TX10 · child
BoughtJun 9, 2021$1K–15KJul 16, 2021
Thomas MacArthur
NJ03 · joint account
SoldMay 27, 2015$1K–15KJun 7, 2015

See a number that looks wrong?